Locus Biosciences
Locus Biosciences raises $152M Series C at $600M valuation
Locus Biosciences: Series C Funding Round
Locus Biosciences has successfully raised $152M in Series C funding, reaching a valuation of $600M.
Company Overview
CRISPR-edited bacteriophages
Funding Details
The Series C round was led by Johnson & Johnson, with participation from Longitude Capital, Braeburn Capital, Domain Associates.
Company Information
- Headquarters: 9201 University City Boulevard, Charlotte, NC 28223
- Founded: 2015
- Employees: 150+
- Category: Biotech
Investment
Locus Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Johnson & Johnson: Verified investor in Series C
- Longitude Capital: Verified investor in Series C
- Braeburn Capital: Verified investor in Series C
- Domain Associates: Verified investor in Series C
Company Info
Investors (4)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free